[go: up one dir, main page]

CA2444691A1 - Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon - Google Patents

Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon Download PDF

Info

Publication number
CA2444691A1
CA2444691A1 CA002444691A CA2444691A CA2444691A1 CA 2444691 A1 CA2444691 A1 CA 2444691A1 CA 002444691 A CA002444691 A CA 002444691A CA 2444691 A CA2444691 A CA 2444691A CA 2444691 A1 CA2444691 A1 CA 2444691A1
Authority
CA
Canada
Prior art keywords
lung cancer
sequence
protein
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002444691A
Other languages
English (en)
Inventor
Natasha Aziz
Richard Murray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2444691A1 publication Critical patent/CA2444691A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention se rapporte à des procédés et à des compositions qui peuvent être utilisés dans le diagnostic et le traitement du cancer du poumon et de pathologies similaires. Cette invention concerne également des procédés qui peuvent être utilisés pour identifier des modulateurs du cancer du poumon et de pathologies similaires.
CA002444691A 2001-04-18 2002-04-18 Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon Abandoned CA2444691A1 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US28477001P 2001-04-18 2001-04-18
US60/284,770 2001-04-18
US29049201P 2001-05-10 2001-05-10
US60/290,492 2001-05-10
US33924501P 2001-11-09 2001-11-09
US60/339,245 2001-11-09
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US33437001P 2001-11-29 2001-11-29
US60/334,370 2001-11-29
US37224602P 2002-04-12 2002-04-12
US60/372,246 2002-04-12
PCT/US2002/012476 WO2002086443A2 (fr) 2001-04-18 2002-04-18 Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon

Publications (1)

Publication Number Publication Date
CA2444691A1 true CA2444691A1 (fr) 2002-10-31

Family

ID=27559574

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002444691A Abandoned CA2444691A1 (fr) 2001-04-18 2002-04-18 Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon

Country Status (5)

Country Link
EP (1) EP1463928A2 (fr)
JP (1) JP2005527180A (fr)
AU (1) AU2002309583A1 (fr)
CA (1) CA2444691A1 (fr)
WO (1) WO2002086443A2 (fr)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168980A1 (fr) * 2000-06-23 2010-03-31 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogenèse
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US7265210B2 (en) 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
EP1385993B8 (fr) 2000-12-08 2011-09-21 Celldex Therapeutics, Inc. Procede de detection et de traitement de pathologies associees au syndrome de la sclerose tubereuse
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
WO2002098356A2 (fr) * 2001-06-05 2002-12-12 Exelixis Inc. Genes de ppp2c en tant que modificateurs de la voie p53 et methodes d'utilisation
WO2003029273A2 (fr) * 2001-09-28 2003-04-10 Whitehead Institute For Biomedical Research Classification de carcinomes pulmonaires par analyse de l'expression genique
US20030175763A1 (en) * 2001-12-20 2003-09-18 Degenhardt Yan Y. Identification of an amplified gene and target for drug intervention
EP1361433A3 (fr) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Méthode de detemination l'efficacité d'une TNF thérapie
DE10225144A1 (de) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2004002514A1 (fr) * 2002-06-26 2004-01-08 Takeda Pharmaceutical Company Limited Substances destinees a la prevention et/ou au traitement du cancer
GB0215224D0 (en) * 2002-07-01 2002-08-14 Inpharmatica Ltd Protein
US7803370B2 (en) 2002-08-30 2010-09-28 Oncotherapy Science, Inc. Method for treating synovial sarcoma
AU2003256079A1 (en) * 2002-08-30 2004-03-19 Japan As Represented By President Of The University Of Tokyo Method for treating synovial sarcoma
WO2004024063A2 (fr) * 2002-09-11 2004-03-25 Genentech, Inc. Compositions et procede de diagnostic et de traitement des tumeurs
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CA2510774A1 (fr) * 2002-12-20 2004-07-15 Avalon Pharmaceuticals Genes cibles cancereux amplifies destines au criblage diagnostique et therapeutique
AU2003292737A1 (en) * 2002-12-24 2004-07-22 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
CA2511522A1 (fr) * 2002-12-26 2004-07-15 Takeda Pharmaceutical Company Limited Nouvelles proteines et leur utilisation
US20070026398A1 (en) * 2003-03-03 2007-02-01 Farnsworth Amanda L Protein tyrosine phosphatase-prl-1 a a marker and therapeutic target for pancreatic cancer
AU2004239362B2 (en) * 2003-03-11 2009-05-14 The University Of British Columbia Diagnosis of gynecological neoplasms by detecting the levels of oviduct-specific glycoprotein
EP1606303A4 (fr) * 2003-03-24 2007-11-21 Corixa Corp La detection et la surveillance d'un cancer du poumon
AU2003901511A0 (en) * 2003-03-28 2003-04-17 Bionomics Limited Nucleic acid molecules associated with angiogenesis II
WO2004097411A1 (fr) 2003-04-25 2004-11-11 Takeda Pharmaceutical Company Limited Nouvelle methode de criblage
WO2004097034A2 (fr) * 2003-05-02 2004-11-11 Bayer Healthcare Ag Agents diagnostiques et therapeutiques destines a des maladies associees a la serine protease 4 transmembranaire humaine (tmprss4)
WO2004111197A2 (fr) * 2003-06-10 2004-12-23 Trustees Of Boston University Signatures d'expression genetique, procedes et compositions permettant de diagnostiquer des troubles des poumons
CA2528572C (fr) * 2003-06-10 2020-08-25 The Trustees Of Boston University Analyse de l'expression genetique des cellules epitheliales de voies aeriennes pour diagnostiquer un cancer du poumon
WO2005002417A2 (fr) * 2003-06-20 2005-01-13 Avalon Pharmaceuticals, Inc. Genes lies au cancer utilises comme cible en chimiotherapie
EP2325338B1 (fr) * 2003-07-17 2015-01-21 Pacific Edge Limited Marqueurs pour la détection du cancer de l'estomac
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
WO2005059109A2 (fr) * 2003-12-15 2005-06-30 The Regents Of The University Of California Signature moleculaire du suppresseur de tumeur pten
JP2008507261A (ja) * 2004-01-27 2008-03-13 コンピュゲン ユーエスエイ，インク． 肺癌診断のための新規のヌクレオチド配列およびアミノ酸配列、ならびにそのアッセイおよび使用方法
US20050186610A1 (en) * 2004-02-20 2005-08-25 Yeon-Su Lee Breast cancer related protein, gene encoding the same, and method of diagnosing breast cancer using the protein and gene
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US7399469B2 (en) * 2004-03-26 2008-07-15 Pdl Biopharma, Inc. Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
JP2005314397A (ja) * 2004-03-31 2005-11-10 Mitsubishi Chemicals Corp 抗コンドロモジュリン−１特異的抗体及びその利用
EP1743944A4 (fr) 2004-04-23 2011-01-05 Takeda Pharmaceutical Nouveau procédé de criblage
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP1753463A2 (fr) 2004-06-01 2007-02-21 Genentech, Inc. Conjugues de medicaments anticorps et procedes correspondants
EP1760087B1 (fr) 2004-06-03 2010-04-21 Takeda Pharmaceutical Company Limited Nouveau complexe proteinique et utilisation de ce complexe
CA2579558A1 (fr) * 2004-09-08 2006-03-16 Ludwig Institute For Cancer Research Antigenes du cancer du testicule
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
US8034578B2 (en) * 2004-10-19 2011-10-11 Oncotherapy Science, Inc. PKP3 oncogene as a prognostic indicator for lung cancer
WO2006084694A2 (fr) * 2005-02-10 2006-08-17 Centre National De La Recherche Scientifique Utilisation du gene mcm8 pour la preparation d'une composition pharmaceutique
PT2325306E (pt) 2005-02-25 2014-04-29 Oncotherapy Science Inc Vacinas peptídicas para cancros do pulmão que expressam polipéptidos ttk, urlc10 ou koc1
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP2360279A1 (fr) 2005-04-14 2011-08-24 Trustees Of Boston University Diagnostic des troubles pulmonaires à l'aide d'une prédiction de classe
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
JP4926168B2 (ja) * 2005-05-13 2012-05-09 オックスフォード バイオメディカ（ユーケー）リミテッド ペプチド
CN101360761B (zh) 2005-12-08 2012-09-12 米德列斯公司 抗蛋白质酪氨酸激酶7（ptk7）的人单克隆抗体及其用途
GB0526498D0 (en) * 2005-12-28 2006-02-08 Randox Lab Ltd Method
AU2007223788B2 (en) 2006-03-09 2012-11-29 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
UA100969C2 (uk) 2006-03-21 2013-02-25 Дженентек, Інк. Антитіло, яке специфічно зв'язує людський альфа5бета1 (alpha5beta1)
JP5298266B2 (ja) * 2006-03-31 2013-09-25 静岡県 小細胞肺癌の判定用キット
JP5114637B2 (ja) * 2006-03-31 2013-01-09 静岡県 小細胞肺癌の判定方法
ES2405618T3 (es) 2006-06-21 2013-05-31 Oncotherapy Science, Inc. Anticuerpos monoclonales dirigidos a tumores para FZD10 y usos de los mismos
DK2032701T3 (da) * 2006-06-23 2014-02-10 Alethia Biotherapeutics Inc Polynukleotider og polypeptider, der er inddraget i cancer
US20100092457A1 (en) 2006-08-14 2010-04-15 Forerunner Pharma Research Co., Ltd. Diagnosis and Treatment of Cancer Using Anti-Desmoglein-3 Antibodies
EP1932854A1 (fr) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides s'apparentant à une protéine de membrane associée à un lysosome (LAMP), ligands correspondants et leur utilisation dans le cadre de la détection et de la purification de cellules dendritiques plasmacytoïdes humaines
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
JP2010528261A (ja) * 2007-05-08 2010-08-19 ピコベラ・リミテッド・ライアビリティ・カンパニー 前立腺癌および肺癌の診断および治療方法
WO2008153814A2 (fr) * 2007-05-29 2008-12-18 President And Fellows Of Harvard College Molécules impliquées dans la régulation de l'activité des ostéoblastes et des ostéoclastes, et leurs méthodes d'utilisation
US8461303B2 (en) 2007-08-02 2013-06-11 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
CN101827936B (zh) 2007-08-20 2014-12-10 肿瘤疗法科学股份有限公司 Cdh3肽以及含有cdh3肽的药剂
BRPI0816150A2 (pt) * 2007-08-24 2019-09-24 Oncotherapy Science Inc genes relacionados com câncer, cdca5, eph47, stk31 e w-dhd1.
WO2009032292A1 (fr) * 2007-09-06 2009-03-12 Case Western Reserve University Procédés de diagnostic et de traitement de cancers
CA2700200A1 (fr) 2007-09-19 2009-03-26 The Trustees Of Boston University Identification de nouvelles voies pour le developpement de medicaments destines a traiter une maladie des poumons
TWI547503B (zh) 2007-09-26 2016-09-01 建南德克公司 抗α5β1抗體、編碼其之核酸、包含其之組合物及其製造及使用方法
WO2010009124A2 (fr) 2008-07-15 2010-01-21 Genentech, Inc. Conjugués de dérivés d’anthracycline, procédé de préparation associé et utilisation comme composés antitumoraux
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010030697A1 (fr) * 2008-09-09 2010-03-18 Somalogic, Inc. Biomarqueurs de cancer du poumon et utilisations associées
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US9290556B2 (en) 2008-09-29 2016-03-22 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
NZ592461A (en) 2008-10-22 2012-12-21 Oncotherapy Science Inc Rab6kifl/kif20a epitope peptide and vaccines containing the same
JP2012506236A (ja) * 2008-10-24 2012-03-15 オンコセラピー・サイエンス株式会社 抗肺がん化合物または抗食道がん化合物のスクリーニング方法
EP3130674B1 (fr) 2008-11-03 2020-07-08 ADC Therapeutics SA Anticorps qui bloquent spécifiquement l'activité biologique d'un antigène tumoral
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
WO2010080769A2 (fr) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Procédés et compositions chimiothérapeutiques
JP5800299B2 (ja) * 2009-02-20 2015-10-28 国立大学法人 東京大学 新規モノクローナル抗体、並びにその使用
MA33210B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Nouveaux anticorps anti-a5b1 et leurs utilisations
EP2427575B1 (fr) 2009-05-07 2018-01-24 Veracyte, Inc. Méthodes pour le diagnostic d'affections thyroïdiennes
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
BR112012008054A2 (pt) 2009-08-21 2017-05-23 Gilead Biologics Inc domínios catalíticos de lisil oxidase e loxl2
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
EP2494361B2 (fr) 2009-10-26 2019-01-09 Externautics S.p.A. Marqueurs de tumeurs des ovaires et leurs méthodes d'utilisation
US8921058B2 (en) 2009-10-26 2014-12-30 Externautics Spa Prostate tumor markers and methods of use thereof
WO2011051278A1 (fr) * 2009-10-26 2011-05-05 Externautics S.P.A. Marqueurs de tumeurs du poumon et leurs méthodes d'utilisation
WO2011088163A1 (fr) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Procédés de modulation de remodélisation et structuration squelettiques par modulation de l'activité de shn2, de l'activité de shn3 ou de l'activité combinée de shn2 et de shn3
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
CN103068406B (zh) 2010-06-08 2017-06-30 基因泰克公司 半胱氨酸改造的抗体和偶联物
SG10201508656VA (en) * 2010-07-09 2015-11-27 Somalogic Inc Lung cancer biomarkers and uses thereof
SG2014007454A (en) 2010-08-13 2014-07-30 Somalogic Inc Pancreatic cancer biomarkers and uses thereof
IL311145B1 (en) 2010-09-29 2025-04-01 Seagen Inc Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
US8937163B2 (en) 2011-03-31 2015-01-20 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
CN103608684B (zh) 2011-05-12 2016-05-04 基因泰克公司 利用框架签名肽检测动物样品中的治疗性抗体的多重反应监测lc-ms/ms方法
CA2850371C (fr) 2011-10-14 2020-06-30 Spirogen Sarl Pyrrolobenzodiazepines et conjugues associes
US20170174753A1 (en) 2012-01-09 2017-06-22 Alethia Biotherapeutics Inc. Method for treating breast cancer
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
WO2014057114A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués pyrrolobenzodiazepine-anticorps anti-psma
ES2703151T3 (es) 2012-10-12 2019-03-07 Adc Therapeutics Sa Conjugados de anticuerpos de pirrolobenzodiazepinas
SI2906296T1 (en) 2012-10-12 2018-06-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN109134599A (zh) 2012-10-12 2019-01-04 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
EP2906297B1 (fr) 2012-10-12 2017-12-06 ADC Therapeutics SA Conjugués anticorps - pyrrolobenzodiazépine
WO2014096365A1 (fr) 2012-12-21 2014-06-26 Spirogen Sàrl Dimères de pyrrolobenzodiazépines asymétriques à utiliser dans le traitement de maladies prolifératives et auto-immunes
CA2894961C (fr) 2012-12-21 2020-09-15 Spirogen Sarl Pyrrolobenzodiazepines et conjugues associes
MX363787B (es) 2013-03-13 2019-04-03 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de los mismos.
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
MX364330B (es) 2013-03-13 2019-04-23 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
WO2014186036A1 (fr) 2013-03-14 2014-11-20 Allegro Diagnostics Corp. Procédés d'évaluation de l'état d'une maladie pulmonaire obstructive chronique (copd)
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054986B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
EP3054985B1 (fr) 2013-10-11 2018-12-26 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
PE20161394A1 (es) 2013-12-16 2017-01-06 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco
CN105828840B (zh) 2013-12-16 2020-08-04 基因泰克公司 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法
MX371092B (es) 2013-12-16 2020-01-16 Genentech Inc Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
WO2016040825A1 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
EP3770274A1 (fr) 2014-11-05 2021-01-27 Veracyte, Inc. Systèmes et procédés de diagnostic de la fibrose pulmonaire idiopathique sur des biopsies transbronchiques à l'aide de l'apprentissage automatique et de données de transcription dimensionnelle élevée
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP6752204B2 (ja) 2014-12-03 2020-09-09 ジェネンテック， インコーポレイテッド 四級アミン化合物及びその抗体−薬物コンジュゲート
ES2952959T3 (es) 2015-03-27 2023-11-07 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra diversos tumores (SEQ ID N.º 25 - MXRA5-003)
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (fr) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Conjugués anticorps-protac et procédés d'utilisation
WO2017205741A1 (fr) 2016-05-27 2017-11-30 Genentech, Inc. Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018009915A1 (fr) 2016-07-08 2018-01-11 Trustees Of Boston University Biomarqueur basé sur l'expression génique pour la détection et la surveillance de lésions précancéreuses bronchiques
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
WO2018065501A1 (fr) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Procédés de préparation de conjugués anticorps-médicament
TWI762516B (zh) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對ｆｚｄ１０之單株抗體及其用途
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
HRP20210979T1 (hr) 2017-02-08 2021-09-17 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protutijelo
AU2018255876B2 (en) 2017-04-18 2020-04-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
MX2019012464A (es) 2017-04-20 2019-12-11 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
HRP20220311T1 (hr) 2017-08-18 2022-05-13 Medimmune Limited Konjugati pirolobenzodiazepina
JP2020534300A (ja) 2017-09-20 2020-11-26 ピーエイチ・ファーマ・カンパニー・リミテッドＰｈ Ｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． タイランスタチン類似体
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (fr) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Inducteurs chimiques conjugués de dégradation et méthodes d'utilisation
JP7514834B2 (ja) 2018-12-03 2024-07-11 アジェンシス，インコーポレイテッド 抗１９１ｐ４ｄ１２抗体薬物コンジュゲートを含む薬学的組成物、およびその使用方法
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
KR20210139270A (ko) 2019-03-15 2021-11-22 메드임뮨 리미티드 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN114163513B (zh) * 2021-03-24 2025-02-25 深圳市新靶向生物科技有限公司 一种与肝癌驱动基因突变相关的抗原肽组合及其应用
EP4426727A2 (fr) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps
DK4294951T3 (da) * 2022-05-13 2025-03-03 Hummingbird Diagnostics Gmbh Hidtil ukendt rna-molekyle til påvisning af kræft
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations
WO2024220546A2 (fr) 2023-04-17 2024-10-24 Peak Bio, Inc. Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires

Also Published As

Publication number Publication date
WO2002086443A2 (fr) 2002-10-31
WO2002086443A8 (fr) 2004-06-17
EP1463928A2 (fr) 2004-10-06
JP2005527180A (ja) 2005-09-15
AU2002309583A1 (en) 2002-11-05

Similar Documents

Publication Publication Date Title
CA2444691A1 (fr) Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
US7736853B2 (en) Methods of diagnosis of androgen-dependent prostate cancer, prostate cancer undergoing androgen withdrawal, and androgen-independent prostate cancer
US7435589B2 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20030124579A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2004063355A2 (fr) Nouveaux procedes de diagnostic d'un cancer metastatique, compositions et procedes de depister des modulateurs du cancer metastatique
CA2453098A1 (fr) Procede de diagnostic du cancer de la vessie, compositions et procedes de criblage de modulateurs du cancer de la vessie
CA2425569A1 (fr) Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
US20040253606A1 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
CA2451465A1 (fr) Procedes de diagnostic du cancer ovarien, compositions et procedes de criblage de modulateurs du cancer ovarien
US20030235820A1 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
US20100297152A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
CA2459219A1 (fr) Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer
US20030232350A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20070054268A1 (en) Methods of diagnosis and prognosis of ovarian cancer
US20070059748A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CA2440703A1 (fr) Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein
CA2438030A1 (fr) Methode de diagnostic de l'angiogenese, preparations et methodes d'identification par criblage de modulateurs de l'angiogenese
US20030228570A1 (en) Methods of diagnosis of Hepatitis C infection, compositions and methods of screening for modulators of Hepatitis C infection
WO2004073657A2 (fr) Methode de diagnostic du cancer, composition et methodes de criblage destinees a identifier des modulateurs du cancer
CA2381699A1 (fr) Nouvelles techniques de diagnostic de l'angiogenese, compositions et techniques de criblage pour modulateurs d'angiogenese
US20040146862A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20080138838A1 (en) Diagnosis of zd1839 resistant tumors
CA2467433A1 (fr) Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
EP1847620A2 (fr) Procédé pour le diagnostic du cancer de la prostate, compositions et procédés pour le dépistage de modulateurs du cancer de la prostate
US20040063108A1 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for modulators of colorectal cancer

Legal Events

Date Code Title Description
FZDE Dead